Commercial launch of Zontivity commences in USA

7 June 2017

The US subsidiary of Canada’s Aralez Pharmaceuticals (TSX: ARZ) today announced that the national commercial launch of Zontivity (vorapaxar) in the USA will commence this week.

Zontivity is the only antiplatelet therapy that inhibits PAR-1-mediated platelet aggregation in response to thrombin. It is a once-daily agent indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or in patients with peripheral arterial disease (PAD), and should be used in combination with daily aspirin and/or clopidogrel according to their indications or standard of care.

In September 2016, Aralez Pharmaceuticals acquired the US and Canadian rights to US pharma giant Merck & Co’s (NYSE: MRK) blood-thinning drug Zontivity. Ahead of the deal with Aralez, Merck announced it would be stopping promotion of the drug, which at one point was forecast to bring in $5 billion worth of sales, following the emergence of serious bleeding risks.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK